phrixus pharmaceuticals

Directory of Companies, Description Source: VentureRadar Research / Company Website, US Small Business Administration (SBA) Award, Amount: $622,877.00 | Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188, Amount: $583,225.00 | Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx mo. Former Chief Executive Officer at Sevion Therapeutics, Inc. Akashi is developing a pipeline of therapies with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. list-style-type: none; San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g.

Information. }

Total amount raised across all funding rounds, Total number of current team members an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward. 155 likes. Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases.

Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts to impact a central problem in rare diseases: rapid therapy development. Phrixus is developing Carmeseal™ (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure.VentureRadar Research / Company Website. Phrixus Pharmaceuticals develops and commercializes heart failure-related pharmaceutical products and therapies.

We generally send out our monthly newsletter at the end of each month.

Entrepreneurs Thomas Collet and Bruce Markham founded Phrixus in 2006 to validate the potential of Carmeseal (P188) to treat heart failure. Associated sectors: Biotech; Small Molecules; Small Molecule Pharmaceuticals; Similar Companies: … [])). Address 1600 HURON PARKWAY BLDG. [])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+[])+(+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![])+(!+[]+(!![])-[])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]))/+((!+[]+(!![])+!![]+[])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]-(!![]))+(+!![])+(!+[]+(!![])-[])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![])+(!+[]+(!![])+!! Access Full Search Results with a Business Account or On Demand Pass, About Us

ACTIVE Biotech ABSwedenPrivateActive Biotech focuses on the research and development of pharmaceuticals in therapeutic areas with high medical need, in which the immune system is of central importance. All rights reserved. } .wpv-loop{ Phrixus is developing Carmeseal™ (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure." Phrixus Pharmaceuticals is a company focused on therapies for Duchenne muscular dystrophy (DMD) and heart failure. Ownership Information.

Terms and Conditions list-style-type: none; Expand your fundraising pool and make warm introductions to potential new business connections.

/* ----------------------------------------- */, Global database oversight committee – TGDOC, A Clinical Outcome Study for Dysferlinopathy, Experimental protocols for DMD animal models, Experimental protocols for SMA animal models, Ongoing updating and dissemination of standards of care for DMD, 2017 Standards of Care for Spinal Muscular Atrophy (SMA), The Guide to the 2017 International Standards of Care for SMA, Previous Standards of Care for Spinal Muscular Atrophy (SMA) 2007, Older guides to the 2007 Standards of Care (available in multiple languages), Standards of Care for Congenital Myopathy (CM), Accredited laboratories for genetic diagnosis, Best practice guidelines for molecular testing published in Neuromuscular Disorders, FDA-NIH workshop on antisense oligonucleotide therapies, Ways to measure clinical effectiveness in the investigation of medicinal products for the treatment of DMD/BMD, Developing a core curriculum for a European neuromuscular fellowship, Post Marketing Surveillance Frequently Asked Questions, TREAT-NMD Post Marketing Surveillance Webinar, TACT : TREAT-NMD Advisory Committee for Therapeutics, Congenital Muscle Disease International Registry, Global Registry for COL6-related dystrophies. The company develops Carmeseal, a therapy for the treatment of heart failure. Phrixus Pharmaceuticals is a company focused on therapies for Duchenne muscular dystrophy (DMD) and heart failure. Submit a Company Phrixus Pharmaceuticals, Inc. develops and commercializes pharmaceuticval s and therapies related to heart failure. The company's heart failure-related pharmaceutical products offer a polymer, carmeseal for the treatment of DMD and acute heart failure by repairing muscle damage, enabling healthcare institutions to avail cost-effective and efficient drugs for quick recovery. padding-left:0px;

VentureRadar Research / Company Website. [])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![]+!![])+(+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(+!![]))/+((!+[]+(!![])+!![]+!![]+[])+(+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![])+(!+[]-(!![]))+(+!![])+(+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!! The company develops Carmeseal, a therapy for the treatment of heart failure. sponsored by Phrixus Pharmaceuticals, Inc.. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. All Rights Reserved. Amount: $306,708.00 | Poloxamer 188 mechanism of action in ischemic heart failure.